Cernevit

/ Teva

1 vial per day.
Intravenous route exclusively.
Adults and Children aged 11 years and above: should receive the contents of one vial (5 ml) per day.
See prescribing information for full details.

Vitamin supplementation in patients receiving parenteral nutrition.
Only for adults and children aged over 11 years of age.

Hypersensitivity to the active constituents, especially vitamin B1 or excipients;
neonates, infants and children less than 11 years old.

See prescribing information for full details.

See prescribing information for full details.

Levodopa and pyridoxine: Vitamin B6 may reduce the effectiveness of L. Dopa as the decarboxylation of L. Dopa requires a vitamin B6 dependent enzyme.
A dopa-decarboxylase inhibitor such as carbidopa can be added to prevent this interaction.
Anticonvulsants and folic acid: Folic acid may increase the metabolism of some antiepileptics, such as phenobarbital, phenytoin and primidone. Plasma concentrations of anticonvulsants should be monitored with concurrent use of folate. Clinical surveillance, eventually, plasma level monitoring, and, if necessary, adjustment of the dose of the anticonvulsant during folic supplementation and after its withdrawal.

Pregnancy: No safety data are available for CERNEVIT administered during pregnancy or in breastfeeding women. This medicinal product may be prescribed during pregnancy if required, providing the indication and dosages are observed in order to avoid vitamin overdose.
Lactation: Use is not recommended during breastfeeding because of the risk of vitamin A overdose in the neonate.

The signs of overdose of CERNEVIT are mostly those resulting from administration of excessive doses of vitamin A.
Clinical signs of acute overdose of Vitamin A (doses exceeding 150,000 IU):
gastrointestinal disorders, headache, raised intracranial pressure, papilloedema, psychiatric disorders, irritability, or even convulsions, delayed generalised desquamation.
Clinical signs of chronic intoxication (prolonged vitamin A supplementation with supraphysiological doses in non-deficient subjects): raised intracranial pressure, cortical hyperostosis of long bones and premature epiphyseal fusion. The diagnosis is generally based on the presence of tender or painful subcutaneous swellings in the extremities of the limbs. X-rays demonstrate diaphyseal periosteal thickening of the ulna, fibula, clavicles and ribs.
Action to be taken in the event of acute or chronic overdose: stop administration of CERNEVIT, reduce calcium intake, increase diuresis and
rehydrate.

Storage: Do not store above 25°C. Keep container in the outer carton.
Protect from heat and light.